X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Daiichi Sankyo And MSD Expand Their ADC Partnership Globally

Content Team by Content Team
19th August 2024
in Drug Development, News
Daiichi Sankyo And MSD Expand Their ADC Partnership Globally

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Daiichi Sankyo and MSD have widened their partnership to create and market three DXd-based antibody-drug conjugates (ADCs) all over the world.

DXd is the name of Daiichi Sankyo’s unique ADC technology platform. MK-6070, MSD’s delta-like ligand 3 (DLL3) targeting T-cell engager, will be part of the deal.

As part of its purchase of Harpoon Therapeutics, MSD got MK-6070.

A Phase I/II clinical study is being done to see if this asset could be used to treat neuroendocrine tumors and small cell lung cancer (SCLC).

The companies will work together to make and sell the MK-6070 all over the world, except in Japan, where MSD will have full rights.

For some people with SCLC, the companies want to look into how MK-6070 might work with other possible combos, like ifinatamab deruxtecan (I-DXd).

Furthermore, MSD will receive $170 million in advance payment in addition to meeting a potential payment promise made in the original deal.

The costs of research and development (R&D) and the money made from selling the MK-6070 around the world (except Japan) will be split evenly between the two companies. Royalties will be distributed to Daiichi Sankyo according to sales.

For splitting the costs of research and development for MK-6070 with ifinatamab deruxtecan, the terms set out in the original deal must be followed.

The new connection builds on the one that Daiichi Sankyo and MSD started in October 2023 when they agreed to work together to make and sell three experimental DXd antibody-drug conjugates.

In Japan, these assets can only be used by Daiichi Sankyo. The three names are raludotatug deruxtecan (R-DXd), ifinatamab deruxtecan (I-DXd), and patritumab deruxtecan (HER3-DXd).

Ken Takeshita, head of research and development at Daiichi Sankyo, says that adding a DLL3 T-cell engager to their oncology pipeline helps them reach their goal of establishing global benchmarks for cancer patient care.

They are excited to grow their relationship with Merck now that MK-6070 is part of it. This is because it shows that they are both committed to finding new ways to help patients and could work well with the way they are already working together on antibody-drug conjugates, especially with ifinatamab deruxtecan.

Previous Post

Ideaya Acquires The B7H3/PTK7 BsADC Rights in $400M Deal

Next Post

Lilly opens state-of-the-art research and development center in the Boston Seaport

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
Lilly to invest $400m to boost manufacturing capacity in US

Lilly opens state-of-the-art research and development center in the Boston Seaport

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In